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Chloroquine (CQ) is exploited inclinical trials as an autophagy
blocker to potentiate anticancer therapy,
but it is unknown if it solely acts by
inhibiting cancer cell-autonomous
autophagy. Our recent study shows that
besides blocking cancer cell growth, CQ
also affects endothelial cells (ECs) and
promotes tumor vessel normalization.
This vessel normalizing effect of CQ
reduces tumor hypoxia, cancer cell intra-
vasation, and metastasis, while improving
the delivery and response to chemother-
apy. By compromising autophagy in mel-
anoma cells or using mice with a
conditional knockout of ATG5 in ECs,
we found that the favorable effects of CQ
on the tumor vasculature do not rely on
autophagy. CQ-induced vessel normali-
zation relies mainly on altered endolyso-
somal trafficking and sustained
NOTCH1 signaling in ECs. Remarkably
these CQ-mediated effects are abrogated
when tumors are grown in mice harbor-
ing EC-specific deletion of NOTCH1.
The autophagy-independent vessel nor-
malization by CQ leading to improved
delivery and tumor response to chemo-
therapy further advocates its clinical use
in combination with anticancer
treatments.
One of the latest issues of Autophagy,
dedicated to translational or clinical
research, highlighted the promising anti-
cancer therapy potentiating effects of CQ
or hydroxychloroquine (HCQ) emerging
from ongoing clinical trials. CQ, an old
antimalarial agent with acceptable safety
profile and recognized evidence of efficacy,
is currently being tested in multiple
clinical trials for numerous late-stage can-
cers including breast, lung, prostate, and
melanoma, either as monotherapy or com-
bined with other anticancer modalities.
CQ is a weak base that accumulates in
acidic organelles, for example, late endo-
somes and lysosomes, where it affects
fusion events and disrupts degradation
by alkalinizing these compartments,
thus compromising autophagosome
turnover.
The propagation of CQ/HCQ in clini-
cal trials is based on the assumption that
when malignant cells become reliant on
autophagy for survival and growth, CQ/
HCQ will sensitize cancer cells to killing by
anticancer treatments by curtailing autoph-
agy. In support of this, a plethora of in vitro
studies have validated the autophagy-inhib-
itory efficacy of CQ, and its ability to phe-
nocopy the effects of more specific
approaches, obtained by knocking down or
knocking out essential autophagy genes, in
vivo. However, a concern has been growing
during recent years in the autophagy
community that besides inhibiting autoph-
agy in cancer cells, CQmay also (or perhaps
mainly) exert its anticancer effects
through autophagy-independent functions.
Through blockage of lysosomal functions
and endosomal trafficking, CQ could
indeed have other anticancer effects, but
their nature remained largely unidentified.
Moreover, current efforts to explore the
effects of CQ mainly focused on malignant
cells, whereas it is becoming increasingly
evident that the crosstalk between cancer
and stromal cells influences tumor behavior
and the responses to anticancer drugs.
Driven by these uncertainties, we asked
whether CQ affects tumor growth by
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inhibiting only autophagy, and whether
the cancer cells in the tumor stroma
represent the major targets of the thera-
peutic effects of CQ. Using melanoma,
a known autophagy-sustained cancer
model, we found that CQ treatment of
tumor-bearing mice dose-dependently
decreases tumor growth, in line with
previous reports. Curiously, however,
we noticed that CQ fails to affect pri-
mary tumor growth, at doses that still
blunt metastasis. When analyzing the
tumor stroma, we observed that CQ
treatment not only ameliorates the
tumor micro-environment and reduces
tumor hypoxia, but also decreases can-
cer cell invasion, intravasation, and dis-
semination. Furthermore, CQ improves
the abnormal structure and function of
tumor blood vessels, through a process
known as ‘vessel normalization.’ At the
structural level, CQ reduces vessel den-
sity and tortuosity and improves
endothelial cell alignment and tight
junction formation. This CQ-induced
vessel normalization effect ameliorates
tumor vessel function, characterized by
improved perfusion, reduced leakiness
and decreased intratumoral hypoxia,
properties that are accompanied by
reduced cancer cell intravasation,
increased drug delivery, and enhanced
chemotherapy response.
But are these effects of CQ reliant on
autophagy inhibition in the cancer cells
and/or endothelial cells? To address these
relevant questions we genetically inter-
fered with either melanoma cell- or EC-
intrinsic autophagy by repressing ATG5
expression in these cells. We observed that
compromising melanoma cell-autophagy
blunts tumor growth and dissemination at
steps of the metastatic cascade down-
stream to tumor cell intravasation but,
most importantly, fails to induce tumor
vessel normalization. Strikingly, we found
that growing melanoma in mice harboring
an EC-specific Atg5 knockout evoked a
cancer phenotype hallmarked by a tumor
vasculature displaying increased—not
decreased—structural and functional
abnormalities. These observations alto-
gether demonstrate that the improvement
of the tumor vasculature and tumor
microenvironment observed after systemic
CQ treatment occur largely through
autophagy-independent effects.
Which are then the molecular mech-
anisms underpinning the tumor vascula-
ture normalizing effects of CQ? We
focused on lysosomal function and
angiogenic receptor trafficking in ECs
after CQ treatment in vitro. We found
that the enlarged and disturbed late
endosomal/lysosomal compartments
caused by CQ-treatment result in
altered endosomal trafficking and sus-
tained signaling/transcriptional activity
of NOTCH1 in ECs. Intriguingly,
none of these CQ-mediated effects on
NOTCH1 are phenocopied by inhibit-
ing ATG5-mediated autophagy in ECs,
again indicating a model whereby CQ
affects the EC phenotype through a
NOTCH1-reliant, autophagy-dispens-
able mechanism.
Is NOTCH1 a bona fide target of
CQ in vivo? To answer this question
we implanted melanoma tumors in
mice lacking Notch1 in ECs. Remark-
ably, both CQ-induced vessel normali-
zation and antimetastatic effects are
ablated in these animals, thus validating
the vital role of NOTCH1 for the anti-
tumor effects of CQ in vivo. Consider-
ing that vessel normalization rather
than pruning is emerging as an increas-
ingly important therapeutic goal, espe-
cially for its ability to lower
intratumoral hypoxia, and the lack of
clinically available ‘vessel normalizing’
agents, the effects of CQ are appealing
and urge further clinical validation.
Moreover, as tumor hypoxia is known
to boycott antitumor immunity, CQ, in
spite of its mild immunosuppressant
activity, may ultimately facilitate
immune responses, a conjecture that
requires further analysis. Considering
that metastasis is the main cause of a
cancer patient’s death, the improved
barrier function of a normalized tumor
Figure 1. Chloroquine normalizes tumor vasculature and blocks cancer cell-autophagy. The figure
schematically illustrates the dual targeting of the tumor by chloroquine. On the one hand, CQ
blocks autophagy in cancer cells, thereby reducing cancer cell proliferation and increasing thera-
peutic response. On the other hand, CQ normalizes the tumor vasculature, thereby reducing cancer
cell intravasation, metastasis, tumor invasiveness and hypoxia, and improving chemodelivery and
chemoresponse. Please refer to the text for further explanation.
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vasculature, impeding cancer cell dis-
semination, observed after CQ treat-
ment, is auspicious. In the future, the
dual effects of CQ as cancer cell
autophagy-inhibitor and vessel-normal-
izing agent, as depicted in Figure 1,
should be considered when developing
protocols and CQ-based therapeutic
regimens.
Chloroquine, one of the oldest drugs
still used in practice today, reveals its
secrets.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were
disclosed.
2084 Volume 10 Issue 11Autophagy
D
ow
nl
oa
de
d 
by
 [K
U 
Le
uv
en
 U
niv
ers
ity
 L
ibr
ary
] a
t 0
2:2
9 1
6 M
arc
h 2
01
5 
